Int J Biol Sci 2020; 16(9):1648-1657. doi:10.7150/ijbs.43117 This issue

Research Paper

USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2

Ning Dou, Qingqing Hu, Li Li, Qiong Wu, Yandong Li, Yong Gao

Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Dou N, Hu Q, Li L, Wu Q, Li Y, Gao Y. USP32 promotes tumorigenesis and chemoresistance in gastric carcinoma via upregulation of SMAD2. Int J Biol Sci 2020; 16(9):1648-1657. doi:10.7150/ijbs.43117. Available from https://www.ijbs.com/v16p1648.htm

File import instruction

Abstract

Graphic abstract

USP32, a member of the ubiquitin-specific proteases family, has been implicated in the development of breast cancer and small lung cancer. However, its biological functions and clinical significance in gastric cancer (GC) remain unclear. In the present study, we reported that knockdown or depletion of USP32 significantly inhibited GC cell proliferation and migration in vitro and in vivo, indicating that USP32 functions as an oncogene in GC. Importantly, results from immunohistochemical staining in a tissue microarray revealed that USP32 was upregulated in GC tissues compared with paracancerous tissues. Further analyses showed that high expression of USP32 was closely related with high T-staging and poor outcomes of GC patients. Mechanistically, USP32 silencing caused a decrease in the expression of SMAD2, which resulted in the inhibitory effects of GC cells on growth, motility, and chemoresistance to cisplatin. Therefore, our findings strongly suggest the involvement of USP32 in GC progression and provide a potential target for future therapy of GC.

Keywords: USP32, SMAD2, gastric carcinoma, drug resistance